Urokinase and macrophages in tumour angiogenesis

British Journal of Cancer

Volumn 72, Issue 4, 1995, Pages 818-823

  Hildenbrand, R ^a   Dilger, I ^a   Horlin A ^a   Stutte, H J ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Angiogenesis; Breast cancer; Macrophages; Urokinase; Vascular invasion

Indexed keywords

BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MACROPHAGE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TUMOR VASCULARIZATION;

BREAST NEOPLASMS; FEMALE; HUMANS; MACROPHAGES; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; URINARY PLASMINOGEN ACTIVATOR;

EID: 0028871316     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1995.419     Document Type: Article

References (34)

1. ASSOIAN RK, FLEURDELYS BE, STEVENSON HC, MILLER PJ, MADTES DK, RAINES EW, ROSS R, AND SPORN MB, (1987). Expression and secretion of type β transforming growth factor by activated human macrophages. Proc. Natl Acad. Aci. USA, 84, 6020–6024.
2. BERSE B, BROWN LF, VAN DE WATER L, DVORAK HF, AND SENGER DR, (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumours. Mol. Biol. Cell, 3, 211.
3. BROWN LF, DVORAK AM, AND DVORAK HF, (1989). Leaky vessels, fibrin deposition and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am. Rev. Respir. Dis., 140, 1104–1107.
4. CORDELL IL, FALINI B, ERBER WN, GOSH AK, ABDULAZIZ Z, MACDONALD S, PULFORD KAF, STEIN H, AND MASON DY, (1984). Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J, Histochem. Cytochem., 32, 219–229.
5. DANO K, ANDREASEN PA, GRONDAHL-HANSEN J, KRISTENSEN P, NIELSEN LS, AND SKRIVER L, (1985). Plasminogen activators. Tissue degradation and cancer. Adv. Cancer Res., 44, 139–266.
6. DVORAK HF, (1986). Tumors: wounds that do not heal. N. Engl. J. Med., 315, 161–165.
7. FALCONE DJ, MCCAFFREY TA, HAIMOVILZ-FRIEDMAN A, AND GARCIA M, (1993a). Transforming growth factor-β 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J, Cell Physiol, 155, 595–605.
8. FALCONE DJ, MCCAFFREY TA, HAIMOVILZ-FRIEDMAN A, VERGILIO J, AND NICHOLSON AC, (1993b). Macrophage and foam cell release of matrix bound growth factors. Role of plasminogen activation. J, Biol. Chem., 268, 11951–11958.
9. FOEKENS J, (1992). Prognostic value of urokinase type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52, 6101–6105.
10. GELEHRTER TD, BAROUSKI-MILLER J, COLEMAN PL, AND CWINKEL C, (1983). Plasminogen activator inhibitors and hormonal regulation in rat hepatoma cell line HTC, Br. J, Mol. Cell Biochem., 53/54, 11–21.
11. GOLDFARB RH, AND LIOTTA LA, (1986). Proteolytic enzymes in cancer invasion and metastases. Semin. Thromb. Hemostasis., 12, 294–316.
12. GRONDAHL-HANSEN J, CHRISTENSEN IB, AND ROSENQUIST C, (1993). High levels of urokinase type plasminogen activator (uPA) and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513–2521.
13. JANICKE F, SCHMITT M, HAFTER R, HOLLRIEDER A, BABIE R, ULM K, GfISSNER W, AND GRAEFF H, (1990). Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4, 69–78.
14. JANICKE F, SCHMITT M, AND GRAEFF H, (1991). Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their inhibitor PAI-1 in breast cancer. Semin. Thromb. Hemostasis, 17, 303–312.
15. JANICKE F, SCHMIT T, PACHE L, ULM K, HARBECK N, HOFLER H, AND GRAEFF H, (1993). Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res. Treat., 24, 195–208.
16. KOBAYASHI H, SCHMITT M, GORETZKI L, CHUCHOLOWSKI N, CALRETE J, KRAMER M, GONZLER WA, JANICKE F, AND GRAEFF H, (1990). Cathepsin B efficiently activates the soluble and the tumor cell receptor bound form of the proenzyme urokinase type plasminogen activator (pro-uPA). J, Biol. Chem., 266, 5147–5152.
17. LE DOUSSAL V, TUBIANA-HULIN M, FRIEDMAN S, HACENE K, SPYRATOS F, AND BRUNTE M, (1989). Prognostic value of the histologic grade nuclear components of Scarff Bloom Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64, 1914–1921.
18. LIU MM, WANG DL, AND LIU CY, (1990). Interactions between fibrin, collagen and endothelial cells in angiogenesis. Adv. Exp. Med. Biol., 281, 319–331.
19. MAHADEVAN V, AND HART JR, (1990). Metastases and angiogenesis. Acta Oncol., 29, 97–103.
20. MILES A, AND PLOW EF, (1988). Plasminogen receptors: Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis, 2, 61–71.
21. MONTESANO R, PEPPER MS, AND MOHLESTEINLEIN U, (1990). Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelial cells expressing the middle T-oncogene. Cell, 62, 435–445.
22. MOSCATELLI D, GROSS JL, AND RIFKIN DB, (1981). Angiogenic factors stimulate plasminogen activator and collagenase production by capillary endothelium cells. J, Cell. Biol., 91, 201a.
23. MOLLER H, (1992). The Human Mammary Carcinoma. Gustav Fischer: Stuttgart.
24. NAGY JA, BROWN LF, AND SENGER DR, (1989). Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta, 948, 305–326.
25. SATO Y, OKAMURA K, MORIMOTO A, HAMANAKA R, HAMAGUCHI K, SHIMADA T, ONO M, KOHNO K, JAKATA T, AND KUWANO M, (1993). Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. Exp. Cell Res., 204, 223–229.
26. SCHMITT M, ANAMAYA N, HENSCHEN A, HOLLRIEDER A, HAFTER R, GULBA D, JANICKE F, AND GRAEFF H, (1989). Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase. FEBS, Lett., 255, 83–88.
27. SKRIVER L, LARSON U, KIELBERG V, NIELSEN LS, ANDREASEN PB, KRISTENSEN P, AND DANO K, (1984). Immunocytochemical localisation of urokinase-type plasminogen activator in Lewis lung carcinoma. J, Cell Biol., 99, 753–758.
28. STUMP D, (1986). Purification and characterisation of low molecular weight form of single-chain urokinase-type plasminogen activator. J, Biol. Chem., 261, 17120–17126.
29. THOMPSON WD, SMITH EB, STIRK CM, MARSHALL FI, STOUT AJ, AND KOCCHAR A, (1992). Angiogenic activity of fibrin degradation products is located in fibrin fragment. Eur. J, Pathol., 168, 47–57.
30. VAN NETTEN JP, ASHMEAD BJ, PARKER IG, THORNTON C, FLETCHER D, CAVERS P, AND BRIGDEN ML, (1993). Macrophage-tumor cell associations, a factor in metastasis of breast cancer? J, Leu. Biol., 54, 360–362.
31. VASALLI JD, BACCINO D, AND BELIN D, (1985). A cellular binding site for the Mr 55000 form of the human plasminogen activator urokinase. J, Cell Biol., 100, 86–92.
32. WEST DC, HAPSON IN, ARNOLD F, AND KUMAR, (1985). Angiogenesis induced by degradation products of hyaluronic acid. Science, 228, 1324–1326.
33. WEST DC, AND KUMAR S, (1989). The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp. Cell Res., 183, 179–196.
34. YASUNAGA C, NAKASHIMA Y, AND SUEISHI K, (1989). A role of fibrinolytic activity in angiogenesis. Quantitative assay using in vitro method. Lab. Invest., 61, 698–704.